114 related articles for article (PubMed ID: 27161742)
1. PO-54 - Clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia.
Alberelli MA; Innocenti I; Sica S; Laurenti L; De Candia E
Thromb Res; 2016 Apr; 140 Suppl 1():S196. PubMed ID: 27161742
[TBL] [Abstract][Full Text] [Related]
2. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Dmitrieva EA; Nikitin EA; Ignatova AA; Vorobyev VI; Poletaev AV; Seregina EA; Voronin KA; Polokhov DM; Maschan AA; Novichkova GA; Panteleev MA; Ptushkin VV
J Thromb Haemost; 2020 Oct; 18(10):2672-2684. PubMed ID: 32511880
[TBL] [Abstract][Full Text] [Related]
3. Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
Ninomoto J; Mokatrin A; Kinoshita T; Marimpietri C; Barrett TD; Chang BY; Sukbuntherng J; James DF; Crowther M
Hematology; 2020 Dec; 25(1):112-117. PubMed ID: 32131714
[No Abstract] [Full Text] [Related]
4. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
Lipsky AH; Farooqui MZ; Tian X; Martyr S; Cullinane AM; Nghiem K; Sun C; Valdez J; Niemann CU; Herman SE; Saba N; Soto S; Marti G; Uzel G; Holland SM; Lozier JN; Wiestner A
Haematologica; 2015 Dec; 100(12):1571-8. PubMed ID: 26430171
[TBL] [Abstract][Full Text] [Related]
5. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka L; Drucker C; Skrabs C; Thomas W; Melchardt T; Struve S; Bergmann M; Staber PB; Porpaczy E; Einberger C; Heinz M; Hauswirth A; Raderer M; Pabinger I; Thalhammer R; Egle A; Wendtner CM; Follows G; Hoermann G; Quehenberger P; Jilma B; Jaeger U
Leukemia; 2017 May; 31(5):1117-1122. PubMed ID: 27909342
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of Glanzmann thrombasthenia by whole blood impedance analyzer (MEA) vs. light transmission aggregometry.
Albanyan A; Al-Musa A; AlNounou R; Al Zahrani H; Nasr R; AlJefri A; Saleh M; Malik A; Masmali H; Owaidah T
Int J Lab Hematol; 2015 Aug; 37(4):503-8. PubMed ID: 25537026
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
Kamel S; Horton L; Ysebaert L; Levade M; Burbury K; Tan S; Cole-Sinclair M; Reynolds J; Filshie R; Schischka S; Khot A; Sandhu S; Keating MJ; Nandurkar H; Tam CS
Leukemia; 2015 Apr; 29(4):783-7. PubMed ID: 25138588
[TBL] [Abstract][Full Text] [Related]
8. Assessment of platelet function with light transmission aggregometry in 24 patients supported with a continuous-flow left ventricular assist device: a single-center experience.
Fiore M; James C; Mouton C; Calderon J; Barandon L; Ouattara A; Picard F
J Thorac Cardiovasc Surg; 2014 Dec; 148(6):3119-25.e1. PubMed ID: 25212058
[TBL] [Abstract][Full Text] [Related]
9. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
Azzam K; Cissé-Thiam M; Drouet L
Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
[TBL] [Abstract][Full Text] [Related]
10. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
Aihara M; Kimura A; Chiba Y; Yoshida Y
Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
[TBL] [Abstract][Full Text] [Related]
11. [Measurement of bleeding time and study of thrombocyte aggregation. Standardization of methods, normal values and results in patients with suspected hemorrhagic diathesis].
Thommen D; Sulzer I; Buhrfeind E; Naef R; Furlan M; Lämmle B
Schweiz Med Wochenschr; 1988 Oct; 118(43):1559-67. PubMed ID: 3238391
[TBL] [Abstract][Full Text] [Related]
12. Platelet function and its clinical significance in the myelodysplastic syndromes.
Zeidman A; Sokolover N; Fradin Z; Cohen A; Redlich O; Mittelman M
Hematol J; 2004; 5(3):234-8. PubMed ID: 15167910
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.
Frontroth JP; Hepner M; Sciuccati G; Feliú Torres A; Pieroni G; Bonduel M
Thromb Haemost; 2010 Dec; 104(6):1158-65. PubMed ID: 20941465
[TBL] [Abstract][Full Text] [Related]
14. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease.
Geisen U; Heilmann C; Beyersdorf F; Benk C; Berchtold-Herz M; Schlensak C; Budde U; Zieger B
Eur J Cardiothorac Surg; 2008 Apr; 33(4):679-84. PubMed ID: 18282712
[TBL] [Abstract][Full Text] [Related]
15. Effect of cardiac operation on platelets.
Mohr R; Golan M; Martinowitz U; Rosner E; Goor DA; Ramot B
J Thorac Cardiovasc Surg; 1986 Sep; 92(3 Pt 1):434-41. PubMed ID: 3091948
[TBL] [Abstract][Full Text] [Related]
16. Family studies of patients with reduced ristocetin aggregation and abnormalities of factor VIII and/or platelet function.
Ekert H; Ananthakrishnan R; Muntz RH; Dowling S; D'Souza S
Thromb Haemost; 1976 Aug; 36(1):78-85. PubMed ID: 1087478
[TBL] [Abstract][Full Text] [Related]
17. Adenosine 2A Receptor Activation Amplifies Ibrutinib Antiplatelet Effect; Implications in Chronic Lymphocytic Leukemia.
Elaskalani O; Gilmore G; Hagger M; Baker RI; Metharom P
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497231
[TBL] [Abstract][Full Text] [Related]
18. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib.
Bye AP; Unsworth AJ; Desborough MJ; Hildyard CAT; Appleby N; Bruce D; Kriek N; Nock SH; Sage T; Hughes CE; Gibbins JM
Blood Adv; 2017 Dec; 1(26):2610-2623. PubMed ID: 29296914
[TBL] [Abstract][Full Text] [Related]
19. Platelet function in chronic leukemias.
Naresh KN; Sivasankaran P; Veliath AJ
Indian J Cancer; 1992 Jun; 29(2):49-55. PubMed ID: 1473832
[TBL] [Abstract][Full Text] [Related]
20. [Identification of human platelet specific functional antibody and its fragments].
Chu XX; Hou M; Zhu YY; Peng J; Ji XB; Zhang F; Wang L
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3464-8. PubMed ID: 16686061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]